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Abstract
Background: A decoction comprised of Nigella sativa seeds, Hemidesmus indicus root bark and Smilax
glabra rhizome is being recommended for cancer patients by a family of traditional medical practitioners
of Sri Lanka. Previous investigations have demonstrated that a short term (10 weeks) treatment with the
decoction can significantly inhibit diethylnitrosamine (DEN) mediated expression of Glutathione S-
transferase P form (GST-P) in rat liver. The objective of the present investigation was to determine
whether long term (16 months) treatment with the decoction would be successful in inhibiting in rat livers,
not only DEN- mediated expression of GST-P, but also the carcinogen mediated development of overt
tumours (OT) or histopathological changes leading to tumour development (HT).
Methods: Thirty-six male Wistar rats were divided into 3 groups of 12 each. Groups 1 and 2 were
injected intraperitoneally (i.p) with DEN (200 mg/kg) while group 3 was injected normal saline (NS).
Twenty-four hours later, decoction (DC; 6 g/kg body weight/day) was orally administered to group 1 rats,
while groups 2 and 3 (DEN-control and normal control) were given distilled water (DW). Treatment with
DC or DW continued for 16 months. At the end of the 9th month and 16th months (study 1 and study 2
respectively), six rats from each group were sacrificed, and livers observed for OT or HT, both visually
and by subjecting liver sections to staining with Haemotoxylin and Eosin (H & E), Sweet's Silver stain (for
reticulin fibers), Periodic Acid Schiff (PAS) staining (for glycogen), and immunohistochemical staining (for
GST-P).
Results: At the end of 9 months (study 1) a hepatocellular adenoma (HA) developed in one of the rats in
the DEN + DW treated group (group 2). At the end of 16 months (study 2), livers of all rats of group 2
developed OT and HT. Large areas of GST-P positive foci were also observed. No OT, HT or GST-P
positive foci were detected in any of the other groups.
Conclusion: Protection against DEN-mediated carcinogenic changes in rat liver can be achieved by long
term treatment with the DC comprised of N. sativa seeds, S. glabra rhizome and H. indicus root bark.
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Background
Traditional and Ayurvedic Physicians in Sri Lanka use sev-
eral plant-based remedies for treatment of cancer with var-
ying degrees of success. However, until recently, none of
these preparations have been subjected to any form of sci-
entifically controlled investigation to determine their effi-
cacy as curative or palliate agents against cancer. A herbal
remedy prescribed to cancer patients by the Jayathilake
family of Ayurvedic physicians (personal communication,
Ayurvedic Dr. Nimal Jayathilake) is a decoction (DC) pre-
pared from Nigella sativa seeds, Hemidesmus indicus root
and  Smilax glabra rhizome. A recent investigation by
Iddamaldeniya et al [1] demonstrated that short-term (10
weeks) treatment of rats with the DC can protect their liv-
ers against DEN- mediated expression of the P-isoform of
Glutathione S-transferase (GST-P). The objective of the
present study was to determine the long-term anti-hepato-
carcinogenic effects of the DC. This was achieved by
assessing the ability of the DC to inhibit diethylnitro-
samine (DEN)-mediated expression of GST-P, as well as
the development of overt tumours (OT) and histopatho-
logical changes leading to tumour development (HT), in
livers of rats treated with the carcinogen.
Methods
Experimental animals
In all experiments Wistar rats (8 week old littermates, 190
± 10 g) purchased from the Medical Research Institute, Sri
Lanka (MRI), were used and maintained in a temperature
controlled room (25°C ± 12°C) under 12 hours light/
dark cycle (dark phase 6 p.m. to 6 a.m.). The Wistar strain
that originated from the Wistar Institute of Biology, USA
and introduced into CLEA, Japan were introduced to the
Animal House, MRI, Sri Lanka in 1990.
Rats were fed with a standard laboratory diet containing
19% crude proteins, 3.8% fibre and 4400 kcal of energy,
prepared by the Medical Research Institute, Sri Lanka,
based on a formula recommended by the WHO, and
water ad libitum [2]. The feed was prepared from ingredi-
ents purchased from several companies. Thus, Maize
meal, Milk powder, Wheat flour and Mollasses were pur-
chased from Ceylon Grain Elevators, Ceylon Milk Foods,
Ceylon Wholesale Establishment, and Sugar factory, Hin-
gurana. Sri Lanka, respectively. Fish Meal (Danish 999)
was imported by the MRl, directly from Denmark. All
other ingredients were supplied by S. V.K. and Sons,
Colombo, Sri Lanka.
Plant material
Dried rhizome of Smilax glabra, dried seed of Nigella sativa
and dried root of Hemidesmus indicus were purchased
locally from Nandana Ayurveda Drug Suppliers, Maharag-
ama, Sri Lanka and identities were confirmed by the Bot-
anist (Mr.Gunarathne Silva), Bandaranayake Memorial
Ayurveda Research Institute, Navinna, Maharagama, Sri
Lanka. A single batch of dried plant material purchased
initially was used throughout the experimental period, to
avoid batch- to-batch variations.
Chemicals
Diethylnitrosamine (DEN) and Diaminobenzidine
(DAB) were purchased from Sigma Diagnostics Inc. USA
Normal Swine serum, Rabbit polyclonal anti GST -P anti-
body, Biotin labeled anti Rabbit IgG and Avidin Biotin-
peroxidase Complex (ABC) were purchased from DAKO,
Denmark. All other chemicals were purchased from Sigma
Chemicals, USA.
Preparation of the decoction
The plant decoction was prepared according to the
method recommended traditionally for administration to
cancer patients (information provided by Dr. N. Jayathit-
lake, Bandaranayake Memoria1 Ayurvedic Research lnsti-
tute, Navinna, Maharagama, Sri Lanka.)
Twenty grams each of Nigella sativa (seeds), Hemidesmus
indicus (root) and Smilax glabra (rhizome) were mixed and
boiled in 1.6 l of distilled water and the final volume was
reduced to 200 m1 by boiling over 3 hours.
Dosage and administration of decoction
The decoction was administered at a dose of 6 g/kg/day to
rats using a Sondi needle by gastric gavage method. This
dose was used in all experiments, as it proved to be the
most effective dose in the short term study conducted pre-
viously [1].
Ethical approval
Ethical approval for the study was granted by the Ethical
Committee of the University of Sri Jayawardenapura, Sri
Lanka.
Experimental procedure
Thirty-six Wistar rats were randomly divided into 3 groups
of 12 each. Groups 1 and 2 were injected with DEN (200
mg/kg) to initiate hepatocarcinogenesis [3] while group 3
was given normal saline (NS) i.p. Twenty-four hours later
the DC (6 g/kg body weight/day) was orally administered
to group 1 rats, while groups 2 and 3 were given same vol-
ume (3 ml) of distilled water (DW). Oral feeding contin-
ued for two weeks after which all rats were subjected to 2/
3 partial hepatectomy (PH) by the technique recom-
mended by Higgins and Anderson [4], to promote hepa-
tocarcinogenesis. On the following day, oral feeding was
resumed and continued for a total of 16 months. At end
of the 9th months (study 1) and 16th month (study 2), six
rats from each group respectively, were sacrificed and liv-
ers examined for OT and tumour like lesions (TL). Sam-
ples of livers were also excised and processed forJournal of Carcinogenesis 2006, 5:11 http://www.carcinogenesis.com/content/5/1/11
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assessment of DEN-mediated histopathological changes
related to hepatocarcinogenesis (HT) as well as GST-P
expression.
Tissue processing and staining
At autopsy, livers were excised from all animals, and slices
of 2–3 mm thick (six slices of liver, two each from the
right posterior, right anterior and caudate lobes) were cut
with a surgical blade, fixed in 10% phosphate buffered
formalin. The samples were procssed using a tissue proc-
essor and embedded in paraffin. Paraffin blocks were cut
using a micro tome cutter. Three sets of the liver sections
from study 1 were subjected to Haemotoxylin and Eosin
(H & E) staining, Silver staining for reticulin fibers, and
Immunohistochemical staining for Glutathione S-trans-
ferase P form (GST -P). Sections from rats in study 2 were
stained with all the above stains, as well as the Periodic
Acid Schiff (PAS) stain (with and without Diastase) for
detection of glycogen.
The method described by Alan and Ian [5] was employed
in making H & E stained sections. The Silver staining
method described by Gorden and Sweet [6] was employed
to stain reticulin fibres in liver sections, while PAS staining
was conducted according to the method described by
McManus [7].
GST -P immunohistochemistry
The Avidin Biotin peroxidase Complex (ABC) method
described by Hsu et al [8] was used to demonstrate GST -
P liver foci. Deparaffinized sections were treated with nor-
mal swine serum (1: 10), rabbit po1yc1onal anti GST -P
antibody (1:150), biotin labeled anti rabbit IgG (1:300)
and ABC. The sites of peroxidase binding were visualized
using Diaminobenzidine (DAB). Sections were counter
stained with Carazzis Haematoxylin for microscopic
examination. As positive control for the specificity of anti-
GST -P antibody binding human thyroid sections were
used. The number of foci and number of cells/cm2 were
measured using an OLYMPUS research microscope
(×400). The final numbers for each parameter were com-
puted after microscopic examination of the whole area of
each section.
The above parameters were quantified in the prepared
liver sections by Prof. N. Ratnatunge (pathologist Faculty
of Medicine, University of Peradeniya, Sri Lanka), who
was blind to the identities of the samples.
Hepatocellular Adenoma 9 months after DEN + DW treat- ment Figure 1
Hepatocellular Adenoma 9 months after DEN + DW treat-
ment. H & E staining (×4)
Hepatocellular carcinoma 16 months after DEN + DW treat- ment Figure 2
Hepatocellular carcinoma 16 months after DEN + DW treat-
ment.
A liver from the group which received DEN + DC for 16  months Figure 3
A liver from the group which received DEN + DC for 16 
months.Journal of Carcinogenesis 2006, 5:11 http://www.carcinogenesis.com/content/5/1/11
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Statistical analysis
The results are expressed as Mean ± Standard Error of
Mean (S.E.M). The significance of difference in the
number of GST-P positive foci between the control and
test groups were analyzed by the Student's t-test.
Results
On examination of rat livers at the end of 9 months, a
hepatocellular adenoma was observed in only one of the
rats in group 2 (DEN + DW) (Fig 1). However, by the end
of the 16th month, overt tumours (OT) or tumour like
lesions (TL) were observed visually (Fig. 2) in livers of all
rats in this group. In contrast, no OT or TL were observed
in the post-mortem, in either rats from this group 1
(DEN+ DC) or group 3 (NS + DW), even at the end of 16
months (Fig. 3), although the livers of group 1 animals
appeared to be hyper plastic, with some adhesions.
H & E staining revealed in all rats of group 3 (NS + DW),
the typical architecture expected of normal livers, even at
the end of 16 months. On the other hand, H & E staining
of livers of group 2 rats (DEN + DW) at the end of 9
months, revealed severe and diffused granular degenera-
tion and cell swelling; At the end of 16 months, growing
hepatocellular carcinomas were evident in livers of all rats
in this group (Fig.4). One of the most notable features
observed in livers of this group, was the extensive angio-
genesis. Although a mild to moderate degree of granular
and vacuolar degeneration were observed in livers of
group 1 (DEN + DC) rats at the end of 16 months, the
degree of such degenerative changes, as well as angiogen-
esis in livers of this group, were of much less intensity
than those seen in group 2 rats (Fig. 5).
As expected, silver staining revealed a normal black
stained reticulin framework in livers of group 3 rats (NS +
Liver section from group 2 (DEN + DW), H & E, (×10) Figure 4
Liver section from group 2 (DEN + DW), H & E, (×10).
Liver section from group 1 (DEN + DC), H & E, (×10) Figure 5
Liver section from group 1 (DEN + DC), H & E, (×10).
Sweet's Silver staining of group 2 liver section (×40) Figure 6
Sweet's Silver staining of group 2 liver section (×40).
Sweet's Silver staining of group 1 liver section (×40) Figure 7
Sweet's Silver staining of group 1 liver section (×40).Journal of Carcinogenesis 2006, 5:11 http://www.carcinogenesis.com/content/5/1/11
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DW) throughout the experimental period. However, in
group 2 (DEN + DW) animals, silver staining revealed dis-
ruption of the reticulin framework, as evident from the
reduction in staining intensity in some areas. At the end of
16 months, a severe reduction of the reticulin framework
was observed in rats of this group, as demonstrated by the
virtual absence of silver stained reticulin fibres in the liver
sections (Fig. 6). In contrast, in group 1 (DEN + DC) ani-
mals, at the end of 16 months of DC treatment, a return
of the reticular framework towards normal was observed
(Fig. 7).
Further support for the development of hepatocellular
carcinomas in group 2 (DEN + DW) rats, was obtained by
PAS staining. Thus, in these animals, positive staining of
similar intensity was observed in liver sections exposed to
this stain, both with and without diastase (Fig. 8). How-
ever, in livers of group 1 rats (DEN + DC), PAS staining
without diastase was positive while PAS staining with dia-
stase was negative.
As demonstrated in the previous short- term investigation
by Iddamaldeniya et al [1], immunohistochemical stain-
ing revealed large areas of GST-P positive foci in livers of
groups 2 rats (DEN +DW), but not in rats of group 3 (NS
+ DW). In group 1 rats (DEN + DC), in comparison to liv-
ers of group 2 (DEN + DW) animals, there was a signifi-
cant reduction (P < 0.05) in the number of GST-P positive
foci (Fig 9).
Discussion
An increasing number of investigations are being con-
ducted worldwide, to discover natural products that can
suppress or prevent the process of carcinogenesis [9-12]
and [13]. Research on plants have not only confirmed the
presence of potential anticancer components in many
plants used traditionally for the treatment of cancer, but
also helped in the identification of compounds with anti-
cancer activity from non-traditionally used plants, that
have subsequently been developed into clinically useful
drugs [14] and [15].
A recent short-term study by Iddamaldeniya et al. [1], has
shown that diethylnitrosamine (DEN)-induced expres-
sion of the p-isoform of glutathione S-transferase (GST-P)
in rat livers could be significantly inhibited by treatment
of rats for 10 weeks, with the decoction (DC) comprised
of N.sativa seeds, H.indicus roots, and S. glabra rhizome,
that has also been used in the present investigation. From
results obtained, it was concluded that the DC has the
potential to protect against chemically-induced hepato-
carcinogenesis. Results of the present investigation pro-
vide further supportive evidence for this view. Thus, long-
term treatment (for up to 16 months) of rats with the DC
has been demonstrated to inhibit not only DEN-induced
GST-P expression, but also the carcinogen-mediated
development of overt tumours (OT) and histopathologi-
cal changes leading to tumour development (HT) as
assessed both by visual observations and by microscopic
examination of liver sections stained with H&E, Sweet's
silver stain and the PAS stain for glycogen. The above
stains have been used by many other researchers to assess
histopathological changes associated with liver tumour
development [16,17] and [18].
One of the most notable features observed in livers of rats
treated only with DEN, was the extensive angiogenesis
associated with carcinogen-mediated tumours and
tumour-like lesions. In rats treated with DEN and the DC,
PAS staining with diastase, group 2 (×40) Figure 8
PAS staining with diastase, group 2 (×40).
Effects of a decoction treatment for 16 months on number of  DEN-mediated GST-P positive foci in Wistar rats Figure 9
Effects of a decoction treatment for 16 months on number of 
DEN-mediated GST-P positive foci in Wistar rats. Group 1: 
DEN + Decoction. Group 2: DEN + Distilled water. Group 
3: Normal saline + Distilled waterJournal of Carcinogenesis 2006, 5:11 http://www.carcinogenesis.com/content/5/1/11
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a marked reduction of angiogenesis was observed. Inhibi-
tion of angiogenesis is generally considered to be one
method by which tumour growth can be inhibited or
reversed [19-21] and [14]. Recent investigations have
shown that inhibition of angiogenesis is a mechanism by
which many phytochemicals also mediate their anti-can-
cer effects [22-26] and [27]. The anti-angiogenic effects of
these natural products have been shown to be related to
their abilities to reduce inflammation and/or vascular per-
meability, or production of detrimental eicosanoids and
other angiogenic factors [28]. The mechanism/s by which
the DC comprised of N. sativa, H. indicus and S. glabra
inhibits angiogenesis are not clear, although each of the
above plants have been reported to possess strong anti-
inflammatory properties [29-31] and [32]. Further studies
have to be conducted before any definite conclusions can
be reached regarding the mechanism/s by which the DC
mediates anti-angiogenic effects.
Previous investigations have shown that N. sativa seeds
and H. indicus root contain components with strong anti-
oxidant activity [33-35] and [36]. All three of the plants in
the DC have also been shown to possess immunomodu-
latory properties [37-40] and [33]. These properties may
also contribute to the antihepatocarcinogenic actions of
the DC.
Recent in-vivo studies have shown that active principles
isolated from N.sativa seeds and an H.indicus root extract
can inhibit tumour development in mouse skin [41] and
[42]. Principles isolated from N.sativa seeds [41,43] and
[39] and S.glabra  rhizome [44] has also been demon-
strated to be cytotoxic to several human cancer cell lines.
At present, it is not possible to be certain whether only
one of the plants in the DC is mainly responsible for
mediating the observed anti-hepatocarcinogenic effects or
whether all three plants contribute to different extents.
Studies currently being conducted in our laboratory with
extracts of the individual plants in the DC, would hope-




GST-P: Glutathione S-transferase P-isoform
DAB: Diaminobenzidine
ABC: Avidin Biotin-peroxidase Complex
PH: Partial-Hepatectomy
S.E.M: Standard Error of Mean
OT: Overt Tumours
TL: Tumour like Lesions






PAS: Periodic Acid Schiff
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